Abzena
Cambridge, US · Founded 2014 · United Kingdom corporation · 4 known investors
Abzena is an integrated CDMO and CRO providing end-to-end development and cGMP manufacturing services for complex biologics and bioconjugates, including ADCs, AOCs, bispecifics, and HPAPIs. It serves biotech, academic, and pharmaceutical customers across the drug development lifecycle from discovery through commercial manufacturing.
Advanced ManufacturingBiotechHealthtechMedical Devices
Founders & leadership
WJ
William John Edward BurtExecutive
NP
Nigel PitchfordNamed on SEC filing
LP
Leigh PierceNamed on SEC filing
KC
Kenneth CunninghamNamed on SEC filing
JS
Julian SmithNamed on SEC filing
AB
Anthony BramptonNamed on SEC filing
AL
Anker LundemoseNamed on SEC filing
PG
Peter GrantNamed on SEC filing
MB
Matthew BakerNamed on SEC filing
Investors · 4
Reported raises · per SEC filings
Form D private placements$4.3M disclosed across 2 rounds · 2015
▶$3.6MraisedDec 2015 · 2 investors · BiotechnologyRule 506(b)
▶$3.6MraisedDec 2015 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jim MillsExecutive Officer
- Kenneth CunninghamDirector
- Campbell BunceExecutive Officer
- Nareshkumar JainExecutive Officer
- Gary PierceExecutive Officer
- Anker LundemoseDirector
- Julian SmithExecutive Officer, Director
- William John Edward BurtExecutive Officer, Director
- Leigh PierceExecutive Officer
- Nigel PitchfordDirector
- Sally WatermanExecutive Officer
- Matthew BakerExecutive Officer
- Peter GrantDirector
- Anthony BramptonDirector
- Offering amount
- $3.6M
- Amount sold
- $3.6M
- First sale
- Dec 2015
- Incorporated
- Corporation, United Kingdom, 2014
- Federal exemptions
- 06b
▶$700KraisedSep 2015 · 7 investors · BiotechnologyRule 506(b)
▶$700KraisedSep 2015 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nigel PitchfordDirector
- Leigh PierceExecutive Officer
- William John Edward BurtExecutive Officer, Director
- Kenneth CunninghamDirector
- Julian SmithExecutive Officer, Director
- Anthony BramptonDirector
- Anker LundemoseDirector
- Peter GrantDirector
- Matthew BakerExecutive Officer
- Offering amount
- $700K
- Amount sold
- $700K
- First sale
- Sep 2015
- Incorporated
- Corporation, United Kingdom, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Catalent90 shared keywordsCatalent is a global Contract Development and Manufacturing Organization (CDMO) that helps pharma, biotech, and self-care companies develop, manufacture, and deliver drug products and consumer health solutions. Its services span oral dose, biologics, specialty, and clinical supply, from early-stage design through commercial manufacturing.
Pharmaron78 shared keywordsPharmaron is a life science contract research and manufacturing service provider covering drug discovery, preclinical and clinical development, and commercialization. It serves pharmaceutical and biotech partners across small molecules, biologics, and cell and gene therapy (CGT) products.
Contract68 shared keywordsContract Pharma is a trade media publication covering the pharmaceutical and biopharmaceutical industry, with a focus on contract development and manufacturing (CDMO) topics. It provides industry news, magazine issues, expert interviews, webinars, whitepapers, company directories, and event coverage for professionals in the pharma and biopharma sector.
Companies competing with Abzena for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Abzena do?
- Abzena is an integrated CDMO and CRO providing end-to-end development and cGMP manufacturing services for complex biologics and bioconjugates, including ADCs, AOCs, bispecifics, and HPAPIs. It serves biotech, academic, and pharmaceutical customers across the drug development lifecycle from discovery through commercial manufacturing.
- Who are Abzena's investors?
- Abzena's investors include Beringea, BIOSPRING PARTNERS, WCAS, Welsh, Carson, Anderson & Stowe.
- How much funding has Abzena raised?
- Abzena has disclosed $4.3M raised across 2 rounds.
- Where is Abzena headquartered?
- Abzena is headquartered in Cambridge, US.